RMD ResMed Stock Outlook 2026: GLP-1 Fear Is Overdone, Here's the Real Math
ResMed (NYSE: RMD) stock analysis — AirSense 11 platform, Philips recall windfall locked in, GLP-1 impact with real adherence data, Brightree/MatrixCare SaaS margin lift. TTM revenue $5.54B, FCF $1.75B. Bull case, bear case, and where we stand.
RMD ResMed sleep apnea